Camlin Fine Sciences Limited
Camlin Fine Sciences Limited, together with its subsidiaries, research, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers shelf-life solutions, which include basic ingredients, such as tert-butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), and Ascorbyl Palmitate… Read more
Camlin Fine Sciences Limited (CAMLINFINE) - Total Liabilities
Latest total liabilities as of September 2025: ₹11.77 Billion INR
Based on the latest financial reports, Camlin Fine Sciences Limited (CAMLINFINE) has total liabilities worth ₹11.77 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Camlin Fine Sciences Limited - Total Liabilities Trend (2007–2025)
This chart illustrates how Camlin Fine Sciences Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Camlin Fine Sciences Limited Competitors by Total Liabilities
The table below lists competitors of Camlin Fine Sciences Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Innova Captab Limited
NSE:INNOVACAP
|
India | ₹6.71 Billion |
|
Locaweb Serviços de Internet S.A.
SA:LWSA3
|
Brazil | R$1.16 Billion |
|
BioPorto A/S
PINK:THOXF
|
USA | $30.82 Million |
|
Kis Wire
KO:002240
|
Korea | ₩686.56 Billion |
|
CCFNB Bancorp Inc
OTCQX:CCFN
|
USA | $1.47 Billion |
|
Sariguna Primatirta PT
JK:CLEO
|
Indonesia | Rp766.51 Billion |
|
Friedman Industries Inc. Common Stock
NYSE MKT:FRD
|
USA | $172.02 Million |
|
TrueLight
TWO:3234
|
Taiwan | NT$270.56 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Camlin Fine Sciences Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.14 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Camlin Fine Sciences Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Camlin Fine Sciences Limited (2007–2025)
The table below shows the annual total liabilities of Camlin Fine Sciences Limited from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹11.49 Billion | +4.95% |
| 2024-03-31 | ₹10.95 Billion | -11.43% |
| 2023-03-31 | ₹12.36 Billion | +19.42% |
| 2022-03-31 | ₹10.35 Billion | +34.69% |
| 2021-03-31 | ₹7.68 Billion | -0.71% |
| 2020-03-31 | ₹7.74 Billion | +17.89% |
| 2019-03-31 | ₹6.57 Billion | +12.59% |
| 2018-03-31 | ₹5.83 Billion | +31.83% |
| 2017-03-31 | ₹4.42 Billion | +44.32% |
| 2016-03-31 | ₹3.06 Billion | +3.96% |
| 2015-03-31 | ₹2.95 Billion | +5.54% |
| 2014-03-31 | ₹2.79 Billion | -8.14% |
| 2013-03-31 | ₹3.04 Billion | +30.68% |
| 2012-03-31 | ₹2.33 Billion | +68.51% |
| 2011-03-31 | ₹1.38 Billion | +52.13% |
| 2010-03-31 | ₹907.72 Million | +41.38% |
| 2009-03-31 | ₹642.05 Million | +62.34% |
| 2008-03-31 | ₹395.50 Million | +4.62% |
| 2007-03-31 | ₹378.01 Million | -- |